Rationale and feasibility of mucin expression profiling by qRT-PCR as diagnostic biomarkers in cytology specimens of pancreatic cancer

Wiktorowicz, Milosz; Młynarski, Damian; Pach, Radosław; Tomaszewska, Romana; Kulig, Jan; Richter, Piotr; Sierżęga, Marek

doi:10.1016/j.pan.2018.09.008

Cited by 2 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They developed a three-MUC diagnostic model, including MUC3, MUC5AC, and MUC6, which presented the potential to differentiate PC from nonmalignancy. Similarly, Wiktorowicz et al [31] examined mucin expression by PCR and immunohistochemistry in surgical and biopsy specimens from patients with pancreatic, ampullary, common bile duct cancers, and CP. It showed the panel of mucin expression profiling might be valuable in differentiating malignant lesions from PC.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer

et al. 2020

View full text Add to dashboard Cite

Background: Pancreatic cancer (PC) is a highly aggressive tumor with a poor prognosis that lacks specific diagnostic markers. Mucin 5AC (MUC5AC) is a member of the mucin family, a heterogeneous group of high molecular weight, heavily glycosylated proteins that could be either membrane-bound or secreted. This multicentral study is to evaluate the performance of serum MUC5AC in combination with carbohydrate antigen 19-9 (CA19-9) for the diagnosis of PC in Asian. Methods: Sixty-one patients with PC (comprised of early pancreatic cancer [n = 30] and late pancreatic cancer [n = 31] patients), 29 benign control, 35 choledocholithiasis, 25 chronic pancreatitis, and 34 healthy controls, were recruited from two hospitals. Serum levels of MUC5AC were evaluated by commercial ELISA kits. CA19-9 was measured by chemiluminescence immunoassay. The cutoff value of MUC5AC was determined based on optimal sensitivity and specificity. Results: Serum MUC5AC in patients with ] ng/mL) presented higher levels than those in controls. The combined biomarker panel (MUC5AC and CA19-9) presented better performance and improved specificity to differentiate PC from controls (AUC 0.894; 95% CI (0.844-0.943), sensitivity 0.738, specificity 0.886) than CA19-9 (p = 0.043) or MUC5AC alone (p = 0.010); however, the latter two had no difference (p = 0.824). Conclusions: Serum MUC5AC is a potential biomarker for PC. The combination with CA19-9 presents improved specificity and better performance.

show abstract

Section: Discussionmentioning

confidence: 99%